Quanterix Corporation announced the first to market, commercial launch of two novel phospho-tau assays: p‑Tau 205 and p‑Tau 212. The announcement comes alongside Quanterix’s robust presence at the Alzheimer’s Association International Conference (AAIC) 2025, with more than 55 posters and presentations featuring data generated using its Simoa technology.
These new assays enable the precise detection of tau phosphorylation sites, biomarkers increasingly associated with early and progressive stages of Alzheimer’s disease. Developed on Quanterix’s ultra-sensitive Simoa platform, their p‑Tau 205 and 212 assays empower researchers to explore novel disease mechanisms, refine patient stratification, and support therapeutic development through fluid-based biomarkers.
Quanterix also recently acquired Akoya Biosciences, bringing advanced spatial proteomics into its scientific ecosystem. The Human FFPE Neurobiology Panel, originally developed by Akoya, complements the Simoa platform by enabling high-plex, spatially resolved analysis of disease-specific protein expression in brain tissue. Together, these platforms offer researchers a powerful combination of tissue- and fluid-based biomarker discovery to accelerate translation from bench to bedside.
The newly launched p-Tau 205 and p-Tau 212 assays are now available to customers for use on the HD-X or SR-X instruments or testing directly through Quanterix's in-house Accelerator Lab, a CLIA-licensed, ISO 15189-accredited facility providing contract biomarker testing services to global partners in pharma, biotech, and academia.
